AKBA Akebia Therapeutics
$0.43
Akebia Therapeutics (AKBA) Earnings News
Earnings press releases, previews and reviews for Akebia Therapeutics (AKBA), newest first. Our most recent is review: Akebia Misses as Vafseo Destocking and a Sharply Lower Post-TDAPA Price Overshadow Its Best Clinical Evidence Yet.
Thursday
November 5, 2026
10:46 AM ET
Akebia Misses as Vafseo Destocking and a Sharply Lower Post-TDAPA Price Overshadow Its Best Clinical Evidence Yet
Earnings Whispers · Review
Thursday
November 5, 2026
7:10 AM ET
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Thursday
October 29, 2026
11:51 AM ET
Akebia's Vafseo Ramp Faces Its First Post-VOICE Test as Auryxia Erosion Drags the Top Line
Earnings Whispers · Preview
Thursday
October 29, 2026
8:00 AM ET
Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights
Wednesday
August 5, 2026
4:05 PM ET
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Wednesday
July 29, 2026
8:00 AM ET
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights